Literature DB >> 9045952

p53 mutations in two patients with intraductal papillary adenoma of the pancreas.

M Kaino1, S Kondoh, S Okita, S Ryozawa, S Hatano, K Shiraishi, S Kaino, T Akiyama, K Okita, T Kawano.   

Abstract

There has been no report on p53 gene mutation in benign human pancreatic intraductal tumors. We examined pancreatic juice and tissue specimens from two patients with intraductal papillary adenoma of the pancreas by polymerase chain reaction-single-strand conformation polymorphism analysis and direct sequencing and found point mutations of p53 gene resulting in amino acid substitutions in exons 6 and 8. Thus, p53 gene mutation may be an early event in the neoplastic process of some pancreatic intraductal tumors and may play an important role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9045952      PMCID: PMC5921029          DOI: 10.1111/j.1349-7006.1996.tb03132.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  15 in total

Review 1.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

4.  p53 overexpression in flat serrated adenomas and flat tubular adenomas of the colorectal mucosa.

Authors:  C A Rubio; M Rodensjö
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 5.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Authors:  G Berrozpe; J Schaeffer; M A Peinado; F X Real; M Perucho
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

7.  Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas.

Authors:  T Hoshi; M Imai; K Ogawa
Journal:  J Surg Oncol       Date:  1994-02       Impact factor: 3.454

8.  p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis.

Authors:  G Casey; Y Yamanaka; H Friess; M S Kobrin; M E Lopez; M Buchler; H G Beger; M Korc
Journal:  Cancer Lett       Date:  1993-05-14       Impact factor: 8.679

9.  K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.

Authors:  H Suwa; T Yoshimura; N Yamaguchi; K Kanehira; T Manabe; M Imamura; H Hiai; M Fukumoto
Journal:  Jpn J Cancer Res       Date:  1994-10

10.  Association of p53 gene mutations with short survival in pancreatic adenocarcinoma.

Authors:  S Nakamori; K Yashima; Y Murakami; O Ishikawa; H Ohigashi; S Imaoka; S Yaegashi; Y Konishi; T Sekiya
Journal:  Jpn J Cancer Res       Date:  1995-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.